JP5615558B2 - 活性ポリオキサゾリンおよびそれを含む組成物 - Google Patents

活性ポリオキサゾリンおよびそれを含む組成物 Download PDF

Info

Publication number
JP5615558B2
JP5615558B2 JP2009551999A JP2009551999A JP5615558B2 JP 5615558 B2 JP5615558 B2 JP 5615558B2 JP 2009551999 A JP2009551999 A JP 2009551999A JP 2009551999 A JP2009551999 A JP 2009551999A JP 5615558 B2 JP5615558 B2 JP 5615558B2
Authority
JP
Japan
Prior art keywords
group
poz
groups
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009551999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529212A (ja
JP2010529212A5 (enExample
Inventor
ハリス，ジエイ・ミルトン
ベントレー，マイケル・デイビツド
ユン，クンサン
フアン，ジーハオ
ベロネーゼ，フランチエスコ・マリア
Original Assignee
セリナ・セラピユーテイツクス・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セリナ・セラピユーテイツクス・インコーポレーテツド filed Critical セリナ・セラピユーテイツクス・インコーポレーテツド
Publication of JP2010529212A publication Critical patent/JP2010529212A/ja
Publication of JP2010529212A5 publication Critical patent/JP2010529212A5/ja
Application granted granted Critical
Publication of JP5615558B2 publication Critical patent/JP5615558B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0233—Polyamines derived from (poly)oxazolines, (poly)oxazines or having pendant acyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/16—Nitrogen-containing compounds
    • C08K5/34—Heterocyclic compounds having nitrogen in the ring
    • C08K5/3412—Heterocyclic compounds having nitrogen in the ring having one nitrogen atom in the ring
    • C08K5/3415—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/04—Polycondensates having nitrogen-containing heterocyclic rings in the main chain; Polyhydrazides; Polyamide acids or similar polyimide precursors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polyethers (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
JP2009551999A 2007-02-28 2008-02-28 活性ポリオキサゾリンおよびそれを含む組成物 Active JP5615558B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89221207P 2007-02-28 2007-02-28
US60/892,212 2007-02-28
PCT/US2008/002626 WO2008106186A2 (en) 2007-02-28 2008-02-28 Activated polyoxazolines and compositions comprising the same

Publications (3)

Publication Number Publication Date
JP2010529212A JP2010529212A (ja) 2010-08-26
JP2010529212A5 JP2010529212A5 (enExample) 2011-04-07
JP5615558B2 true JP5615558B2 (ja) 2014-10-29

Family

ID=39721806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009551999A Active JP5615558B2 (ja) 2007-02-28 2008-02-28 活性ポリオキサゾリンおよびそれを含む組成物

Country Status (6)

Country Link
US (1) US7943141B2 (enExample)
EP (1) EP2134181A4 (enExample)
JP (1) JP5615558B2 (enExample)
KR (2) KR101508617B1 (enExample)
CN (2) CN101686687A (enExample)
WO (1) WO2008106186A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088884B2 (en) * 2007-09-27 2012-01-03 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
US8110651B2 (en) 2008-01-11 2012-02-07 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en) * 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8637466B2 (en) 2008-08-11 2014-01-28 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
WO2010080720A2 (en) 2009-01-12 2010-07-15 Nektar Therapeutics Conjugates of a lysosomal enzyme moiety and a water soluble polymer
KR102591732B1 (ko) 2010-11-12 2023-10-19 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
WO2013020005A2 (en) * 2011-08-03 2013-02-07 Anp Technologies, Inc. Oxazoline polymer compositions and use thereof
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
US8383093B1 (en) 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
JP6178399B2 (ja) * 2012-03-16 2017-08-09 ベンデル アナリティカル ホールディング ビー．ブイ．Ｂｅｎｄｅｒ Ａｎａｌｙｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 求核的に活性化したポリオキサゾリンに由来する架橋ポリマー及び医療製品
EP3929206A1 (en) 2012-11-15 2021-12-29 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
CN103897181B (zh) * 2012-12-27 2017-02-08 张昊 聚合物、其制备方法和应用
US9215876B2 (en) 2014-03-24 2015-12-22 International Business Machines Corporation 1,3,6-dioxazocan-2-ones and antimicrobial cationic polycarbonates therefrom
US9624191B2 (en) 2014-03-24 2017-04-18 International Business Machines Corporation Cyclic carbonate monomers and ring opened polycarbonates therefrom
GB201405391D0 (en) * 2014-03-26 2014-05-07 Applied Biomimetic As Novel polymers and process for making membranes
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
AU2015289329B2 (en) 2014-07-18 2018-12-06 Universiteit Gent Method for the preparation of uniform, high molar mass cyclic imino ether polymers
WO2016019340A1 (en) * 2014-07-31 2016-02-04 Serina Therapeutics, Inc. Polyoxazoline antibody drug conjugates
AU2015328825B2 (en) 2014-10-06 2019-02-21 Gatt Technologies B.V. Tissue-adhesive porous haemostatic product
CA3287719A1 (en) 2015-10-07 2026-03-02 Apellis Pharmaceuticals, Inc. Use of long-acting compstatin analog for treating a complement-mediated disorder
MA47290A (fr) 2015-10-08 2019-11-27 Nektar Therapeutics Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée
CN116059313A (zh) 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法
CN111093688B (zh) 2017-05-15 2025-09-16 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
SG11202000167SA (en) 2017-07-11 2020-02-27 Synthorx Inc Incorporation of unnatural nucleotides and methods thereof
KR20250145137A (ko) 2017-08-03 2025-10-13 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
EP3502217B1 (en) * 2017-11-29 2020-05-27 Infineum International Limited Lubricating oil compositions
US10822569B2 (en) 2018-02-15 2020-11-03 Afton Chemical Corporation Grafted polymer with soot handling properties
WO2019165453A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
US10851324B2 (en) 2018-02-27 2020-12-01 Afton Chemical Corporation Grafted polymer with soot handling properties
CN110865055B (zh) * 2018-08-27 2022-10-25 香港科技大学 无金属偶联方法、偶联物及其应用
US10899989B2 (en) 2018-10-15 2021-01-26 Afton Chemical Corporation Amino acid grafted polymer with soot handling properties
BR112021005401A2 (pt) 2018-11-08 2021-06-29 Synthorx, Inc. conjugados de interleucina 10 e usos dos mesmos
US11046908B2 (en) 2019-01-11 2021-06-29 Afton Chemical Corporation Oxazoline modified dispersants
US20200246467A1 (en) 2019-02-06 2020-08-06 Synthorx, Inc. Il-2 conjugates and methods of use thereof
US12485181B2 (en) 2019-06-28 2025-12-02 Serina Therapeutics (Al), Inc. Polyoxazoline-drug conjugates with novel pharmacokinetic properties
BR112022001554A2 (pt) * 2019-07-30 2022-03-22 Gatt Tech B V Copolímero de polioxazolina, uso do copolímero, produto médico biocompatível e processo de preparação de copolímeros
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
CN114630818A (zh) 2019-09-30 2022-06-14 北京轩义医药科技有限公司 蛋白-大分子偶联物及其使用方法
PH12022552719A1 (en) 2020-04-22 2024-02-05 Merck Sharp & Dohme Llc HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAc DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER
CN117098558A (zh) 2021-02-09 2023-11-21 塞瑞纳治疗公司 聚噁唑啉-脂质缀合物及包含其的脂质纳米颗粒和药物组合物
CN117940158A (zh) 2021-09-03 2024-04-26 库瑞瓦格欧洲公司 用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN118900701A (zh) 2022-01-31 2024-11-05 盖纳万科学有限公司 聚(烷基噁唑啉)-脂质缀合物及含有聚(烷基噁唑啉)-脂质缀合物的脂质颗粒
CN114685784B (zh) * 2022-04-26 2023-09-15 北京清科胜因生物科技有限公司 一种用于核酸递送的聚(2-噁唑啉)脂质与脂质纳米颗粒及应用
CN114940756B (zh) * 2022-06-02 2023-11-07 北京清科胜因生物科技有限公司 一种聚（2-噁唑啉）脂质与脂质纳米颗粒及应用
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates
JP2026509258A (ja) 2023-03-08 2026-03-17 キュアバック エスイー 核酸送達のための新規な脂質ナノ粒子製剤
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy
CN118459756A (zh) * 2024-05-07 2024-08-09 南京师范大学 一种温敏性材料和糖缀合物及其合成方法和在糖固相合成中的应用
EP4656669A1 (en) 2024-05-28 2025-12-03 Arkema France Fluorinated copolymers based on an oligo(2-oxazoline) macromonomer
WO2026055280A1 (en) 2024-09-04 2026-03-12 Sanofi Interleukin 2 (il-2) and cd123 nk cell engager combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2643403B2 (ja) * 1989-01-10 1997-08-20 花王株式会社 ポリ（ｎ―アシルアルキレンイミン）系共重合体及びその用途
US5635571A (en) * 1995-06-30 1997-06-03 Cornell Research Foundation, Inc. Polymerizable macromonomers and polymers prepared therefrom
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
CA2447236A1 (en) * 2001-05-21 2002-11-28 Nektar Therapeutics Pulmonary administration of chemically modified insulin
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP2236161A1 (en) * 2001-10-18 2010-10-06 Nektar Therapeutics Polymer conjugates of opioid antagonists
EP1480657A4 (en) * 2002-02-01 2006-07-05 Intradigm Corp POLYMERS FOR ADMINISTERING PEPTIDES AND SMALL MOLECULES IN VIVO / I
WO2005089805A2 (en) * 2004-03-15 2005-09-29 Nektar Therapeutics Al, Corporation Polymer-based compositions and conjugates of hiv entry inhibitors
US8057821B2 (en) * 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
EP1930361B1 (en) * 2005-09-01 2014-04-16 Japan Science and Technology Agency Random copolymer of oxazoline

Also Published As

Publication number Publication date
CN106046370A (zh) 2016-10-26
KR101508621B1 (ko) 2015-04-07
US7943141B2 (en) 2011-05-17
JP2010529212A (ja) 2010-08-26
KR20090114481A (ko) 2009-11-03
WO2008106186A3 (en) 2008-10-23
US20100069579A1 (en) 2010-03-18
KR101508617B1 (ko) 2015-04-06
CN101686687A (zh) 2010-03-31
WO2008106186A2 (en) 2008-09-04
KR20130125404A (ko) 2013-11-18
EP2134181A2 (en) 2009-12-23
EP2134181A4 (en) 2011-09-28

Similar Documents

Publication Publication Date Title
JP2010529212A (ja) 活性ポリオキサゾリンおよびそれを含む組成物
US9169354B2 (en) Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8088884B2 (en) Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
US9284411B2 (en) Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
WO2019209811A1 (en) Macrocyclic toll-like receptor 7 (tlr7) agonists
US20220193243A1 (en) Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US10864276B2 (en) Activated polyoxazolines and conjugates and compositions comprising the same
Lin Synthesis of Poly (ethylene glycol) Derivatives for Bioconjugation and Surface Patterning

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110210

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130301

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130305

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140401

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140702

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140812

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140910

R150 Certificate of patent or registration of utility model

Ref document number: 5615558

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250